Metabolism
Serine/threonine kinase AMPK upregulates glucose uptake by promoting the expression and function of glucose transporters. AMPK is activated by increased AMP/ATP ratio, resulting from cellular and environmental stress, e.g. low glucose, heat shock, hypoxia and ischemia. AMPK activation positively modulates signaling transductions that refill ATP levels. Moreover, it also stimulates catabolic processes such as fatty acid oxidation and glycolysis through inhibition of ACC and activation of PFK2. AMPK negatively regulates various proteins which are important to ATP-consuming mechanisms, e.g. mTORC2, glycogen synthase, SREBP-1, and TSC2, causing the downregulation/inhibition of gluconeogenesis and glycogen, lipid and protein synthesis.
-
B7846 sodium fluorideSummary: Acid phosphatases inhibitor
-
C4534 N-Arachidonyl MaleimideSummary: monoacylglycerol lipase (MGL) or MGL-like activity inhibitor
-
C4796 EggmanoneSummary: selective inhibitor of PDE4
-
C4758 DarglitazoneSummary: PPARγ agonist with antidiabetic actions
-
C4671 Inosine-5'-monophosphate (sodium salt hydrate)Summary: substrate of IMP dehydrogenase (IMPDH)
-
C4647 β-NicotyrineSummary: cytochrome P450 (CYP) isoforms, CYP2A6 and CYP2A13 inhibitor
-
C4686 2-Acetamidophenyl 5-chloro-2-nitrophenyl sulfideSummary: phosphodiesterase 7 (PDE7) inhibitor
-
C4845 PHGDH-inactiveSummary: inactive analog of the 3-phosphoglycerate dehydrogenase (PHGDH) inhibitors NCT-502 and NCT-503
-
C4691 4-phenyl-1,2,3-ThiadiazoleSummary: selective inhibitor of certain CYP450 enzymes (CYP2B4, CYP2E1)
-
C4805 ML-030Summary: PDE4 inhibitor